Zoetis (ZTS) Projected to Post Quarterly Earnings on Thursday

Zoetis (NYSE:ZTS) is anticipated to announce its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of $1.40 per share and revenue of $2.3612 billion for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:30 AM ET.

Zoetis Stock Performance

Shares of ZTS opened at $128.13 on Wednesday. Zoetis has a 1 year low of $115.25 and a 1 year high of $177.00. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. The stock’s fifty day moving average price is $124.03 and its two-hundred day moving average price is $135.84. The firm has a market cap of $56.47 billion, a PE ratio of 21.57, a PEG ratio of 2.20 and a beta of 0.96.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is currently 35.69%.

Institutional Investors Weigh In On Zoetis

Several large investors have recently added to or reduced their stakes in ZTS. Invesco Ltd. increased its stake in Zoetis by 4.6% in the 3rd quarter. Invesco Ltd. now owns 3,371,032 shares of the company’s stock worth $493,249,000 after acquiring an additional 147,271 shares during the last quarter. Corient Private Wealth LLC boosted its position in shares of Zoetis by 85.9% during the 2nd quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock valued at $400,619,000 after acquiring an additional 1,191,840 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Zoetis by 25.6% during the third quarter. AQR Capital Management LLC now owns 1,538,667 shares of the company’s stock worth $221,937,000 after purchasing an additional 314,047 shares in the last quarter. Worldquant Millennium Advisors LLC increased its position in shares of Zoetis by 737.9% in the second quarter. Worldquant Millennium Advisors LLC now owns 912,477 shares of the company’s stock worth $142,301,000 after purchasing an additional 803,573 shares during the last quarter. Finally, Man Group plc raised its stake in Zoetis by 69.4% in the third quarter. Man Group plc now owns 777,496 shares of the company’s stock valued at $113,763,000 after purchasing an additional 318,613 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of research reports. Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. JPMorgan Chase & Co. cut their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. BTIG Research reissued a “buy” rating and set a $160.00 target price on shares of Zoetis in a report on Wednesday, December 3rd. HSBC set a $140.00 target price on Zoetis in a research report on Wednesday, December 10th. Finally, UBS Group set a $136.00 price target on Zoetis in a research report on Thursday, January 29th. Five analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Zoetis has a consensus rating of “Hold” and a consensus target price of $152.45.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.